

Press release, Oct 3 2005

Karin Hehenberger new Senior Investment Director at SLS Venture

SLS Venture, a Scandinavian venture capital company, has appointed Karin Hehenberger Senior Investment Director. Her most recent assignment was at the NASDAQ-listed company Eytech Pharmaceuticals, where she worked as Senior Director of Scientific and External Affairs.

"Several of SLS Venture's portfolio companies are at the brink of being commercialised, something which means new challenges for the management groups of these companies", said Jonas Frick, Chief Executive Officer of SLS Venture. "It is crucial for the future success of SLS Venture to support the management and take part in developing the strategy of our portfolio companies". "Karin has contributed to rapidly converting a small, privately owned company into a listed company with an FDA approved product – an experience we greatly value".

Karin Hehenberger is a doctor of medicine and has worked as an analyst at the hedge fund companies Galleon Management and Brummer & Partners, as well as a strategy consultant at McKinsey & Co. She holds a doctor's degree in molecular medicine and has performed research at the Joslin Diabetes Center and at Harvard Medical School.

For further information, please contact:

Jonas Frick, Chief Executive Officer SLS Venture, tel +46 8 4507035,
mobile +46 708 913020, e-mail: jonas.frick@slsventure.com

SLS Venture is one of the leading venture capital companies focused on life science in Scandinavia. With a wide experience from research, development and company management within the biotech and pharmaceutical industry as well as a broad network, SLS Venture is an active owner of its portfolio companies. The equity in charge amounts to USD 325 M. The portfolio includes A. Carlsson Research AB, Biolipox AB, Doxa AB, Sophion Bioscience A/S, Aerocrine AB and NeuroNova AB.